Literature DB >> 9045885

Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.

H M Karpoff1, M D'Angelica, S Blair, M D Brownlee, H Federoff, Y Fong.   

Abstract

Previous studies showed that gammaIFN decreases metastatic hepatic tumor growth by stimulating Kupffer cells (KC). The present studies examine whether lymphocyte stimulation via cells engineered to secrete GM-CSF or IL-2 decreases hepatic tumor growth, and whether stimulation of both macrophages and lymphocytes is more effective than either individually. Rats were immunized with irradiated hepatoma cells transduced by herpes viral amplicon vectors containing the genes for GM-CSF, IL-2 or LacZ. On day 18, half of each group was treated with 5 x 10(4) U gammaIFN, or saline intraperitoneally for 3 d. On day 21, all rats received 5 x 10(5) hepatoma cells intrasplenically. On day 41, rats were killed and tumor nodules were counted. Separate rats underwent splenocyte and KC harvest for assessment of lymphocyte- and macrophage-mediated tumor cell kill in vitro. GM-CSF or IL-2 vaccines or gammaIFN decreased tumor nodules significantly (GM-CSF 13+/-4, IL-2 14+/-6 vs. control 75+/-24, P < 0.001). Combination therapy was more effective, and completely eliminated tumor in 4 of 12 IFN-GM-CSF and 8 of 11 IFN-IL-2 animals. Additional rats underwent partial hepatectomy, an immunosuppressive procedure known to accelerate the growth of hepatic tumor, following tumor challenge. Therapy was equally effective in this immunosuppressive setting. Vaccination is associated with enhancement of splenocyte-mediated tumoricidal activity, whereas the effect of gammaIFN is mediated by KC. GM-CSF and IL-2 vaccine therapy and pretreatment with gammaIFN represent effective strategies in reducing hepatic tumor. Combination therapy targets both lymphocytes and macrophages, and is more effective in reducing tumor than either therapy alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045885      PMCID: PMC507865          DOI: 10.1172/JCI119226

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity.

Authors:  H M Karpoff; C Tung; B Ng; Y Fong
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

2.  Factors influencing hepatocyte trafficking during allogeneic hepatocyte transplantation: improved liver sequestration with isolated perfusion.

Authors:  A Picardo; Y Fong; H M Karpoff; S Yeh; L H Blumgart; M F Brennan
Journal:  J Surg Res       Date:  1996-07-01       Impact factor: 2.192

3.  Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production.

Authors:  C Tung; H J Federoff; M Brownlee; H Karpoff; T Weigel; M F Brennan; Y Fong
Journal:  Hum Gene Ther       Date:  1996-12-01       Impact factor: 5.695

4.  Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression.

Authors:  B Lu; H J Federoff
Journal:  Hum Gene Ther       Date:  1995-04       Impact factor: 5.695

5.  Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction.

Authors:  J Abe; H Wakimoto; Y Yoshida; M Aoyagi; K Hirakawa; H Hamada
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon gamma.

Authors:  B Schuurman; G Heuff; R H Beelen; S Meyer
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

7.  Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia.

Authors:  S E Raper; M Grossman; D J Rader; J G Thoene; B J Clark; D M Kolansky; D W Muller; J M Wilson
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

8.  Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.

Authors:  Y Iwanuma; K Kato; H Yagita; K Okumura
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

9.  Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice.

Authors:  E A Mesri; H J Federoff; M Brownlee
Journal:  Circ Res       Date:  1995-02       Impact factor: 17.367

10.  Rat liver macrophages express the 55 kDa tumor necrosis factor receptor: modulation by interferon-gamma, lipopolysaccharide and tumor necrosis factor-alpha.

Authors:  F Zhang; A zur Hausen; R Hoffmann; M Grewe; K Decker
Journal:  Biol Chem Hoppe Seyler       Date:  1994-04
View more
  8 in total

1.  Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration.

Authors:  Fanyin Meng; Heather Francis; Shannon Glaser; Yuyan Han; Sharon DeMorrow; Allison Stokes; Dustin Staloch; Julie Venter; Melanie White; Yoshiyuki Ueno; Lola M Reid; Gianfranco Alpini
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

2.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

3.  Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.

Authors:  J J Bennett; S Malhotra; R J Wong; K Delman; J Zager; M St-Louis; P Johnson; Y Fong
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

4.  Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.

Authors:  M D'Angelica; C Tung; P Allen; M Halterman; K Delman; T Delohery; D Klimstra; M Brownlee; H Federoff; Y Fong
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

5.  Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model.

Authors:  W R Jarnagin; K Delman; D Kooby; S Mastorides; J Zager; M F Brennan; L H Blumgart; H Federoff; Y Fong
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

6.  A systemic antitumor immune response prevents outgrowth of lung tumors after i.v. rechallenge but is not able to prevent growth of experimental liver tumors.

Authors:  Frederieke H van Duijnhoven; Remco I J M Aalbers; Joost Rothbarth; Onno T Terpstra; Peter J K Kuppen
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer.

Authors:  Keith A Delman; Jonathan S Zager; Joseph J Bennett; Sandeep Malhotra; Michael I Ebright; Priscilla F McAuliffe; Marc W Halterman; Howard J Federoff; Yuman Fong
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

8.  Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response.

Authors:  Joyce T Au; Arjun Mittra; Tae Jin Song; Michael Cavnar; Kyonghwa Jun; Joshua Carson; Sepideh Gholami; Dana Haddad; Sebastien Gaujoux; Sebastien Monette; Paula Ezell; Jedd Wolchok; Yuman Fong
Journal:  Surgery       Date:  2013-09       Impact factor: 3.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.